<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571087</url>
  </required_header>
  <id_info>
    <org_study_id>HL_HL140_301</org_study_id>
    <nct_id>NCT03571087</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia</brief_title>
  <official_title>A Multi Center, Randomized, Double-blind, Parallel, Factorial Design, Therapeutic Phase III Study to Evaluate the Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of HL140 in patients with
      primary hypercholesterolemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate that the efficacy of combination drug of
      rosuvastatin/ezetimibe is superior to single rosuvastatin drug and to confirm the safety of
      combination drug of rosuvastatin/ezetimibe
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in LDL-Cholesterol from baseline</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage change(%) in LDL-Cholesterol from baseline at week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in LDL-Cholesterol from baseline</measure>
    <time_frame>Week 4</time_frame>
    <description>Percentage change(%) in LDL-Cholesterol from baseline at week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in TG from baseline</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>Percentage change(%) in TG from baseline at week 4 and week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in TC from baseline</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>Percentage change(%) in TC from baseline at week 4 and week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change in non-HDL-Cholesterol</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>Percentage change(%) in non-HDL-Cholesterol from baseline at week 4 and week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change in HDL-Cholesterol</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>Percentage change(%) in HDL-Cholesterol from baseline at week 4 and week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change weeks in Apo A-I</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>Percentage change(%) in Apo A-I from baseline at week 4 and week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change in Apo B</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>Percentage change(%) in Apo B from baseline at week 4 and week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change in Lipoprotein(a)</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>Percentage change(%) in Lipoprotein(a) from baseline at week 4 and week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of change in hs-CRP</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>Percentage change(%) in hs-CRP from baseline at week 4 and week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reached treatment goals according to NCEP ATP III Guideline</measure>
    <time_frame>Week 4, Week 8</time_frame>
    <description>Percentage(%) of patients reached treatment goal, by NCEP ATP III guideline, at week 4 and week 8</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>HL140 5/10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL140 10/10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL140 20/10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 5mg → HL140 5/10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg
Extension period(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 10mg → HL140 10/10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg
Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 20mg → HL140 20/10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 20mg
Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL140 5/10</intervention_name>
    <description>1) Treatment(W0~W8), Extension(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇
●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo</description>
    <arm_group_label>HL140 5/10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL140 10/10</intervention_name>
    <description>1) Treatment(W0~W8), Extension(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇
○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo</description>
    <arm_group_label>HL140 10/10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL140 20/10</intervention_name>
    <description>1) Treatment(W0~W8), Extension(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇
○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo</description>
    <arm_group_label>HL140 20/10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 5mg → HL140 5/10</intervention_name>
    <description>Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇
○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Extension period(W9~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇
HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo</description>
    <arm_group_label>Rosuvastatin 5mg → HL140 5/10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10mg → HL140 10/10</intervention_name>
    <description>Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇
○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo
Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇
HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo</description>
    <arm_group_label>Rosuvastatin 10mg → HL140 10/10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg → HL140 20/10</intervention_name>
    <description>Treatment(W0~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆
○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg
Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo</description>
    <arm_group_label>Rosuvastatin 20mg → HL140 20/10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged over 19 years

          -  Signed informed consent form

          -  At visit 1 and visit 2, LDL-Cholesterol ≤ 250mg/dL and Triglyceride ≤ 400mg/dL

        Exclusion Criteria:

          -  At visit 1, BMI ≥ 30kg/㎡

          -  Has a history of myopathy or rhabdomyolysis cased by statin treatment, hereditary
             myopathy or family history and hypersensitivity to statin(HMG-CoA reductase inhibitor)
             and component of ezetimibe

          -  Has a Severe renal disorder(Ccr &lt;30mL/min) or nephrotic syndrome

          -  Creatine Kinase &gt; 5 x upper limit of normal

          -  ALT or AST &gt; 3 x upper limit of normal

          -  Has a activity/chronic hepatic disease or HIV-positive

          -  Has a endocrine or metabolic diseases known to affect the serum phospholipid or
             protein

               -  Uncontrolled diabetes mellitus(HbA1c ≥9%)

               -  Hypothyroidism (TSH &gt; 1.5 x upper limit of normal rate at the screening )

          -  Uncontrolled hypertension (SBP ≥180mmHg or DBP ≥110mmHg)

          -  Has a acute arteriopathy(history of unstable angina, cardiac infarction, transient
             ischemic stroke, cerebrovascular disease, coronary artery bypass, coronary
             intervention within 12 weeks prior to screening)

          -  Severe heart failure (NYHA Class III or IV)

          -  Has a drug absorption disorder by gastrointestinal surgery or gastrointestinal
             disorder

          -  History of malignant tumor including myelogenous and lymphoma within 5 years
             (Participation is possible, if the tumor has not recurred for more than 5 years)

          -  Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency
             or glucose-galactose malabsorption

          -  Female subjects of childbearing potential who disagree with the contraceptive
             methods(surgical sterilization, intrauterine device or condoms)

          -  Pregnant or breast-feeding

          -  Patients who have a drug or alcohol abuse or are being treated for psychological
             disorder

          -  Patients who were treated with other investigational drug within 12 weeks prior to
             screening

          -  Other patients who are inappropriate to participate in the study considered by the
             investigator or other study staffs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kisik Kim</last_name>
    <role>Study Chair</role>
    <affiliation>The Catholic University of Korea, Dagu St. Mary's Hospital</affiliation>
  </overall_official>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 17, 2018</study_first_submitted>
  <study_first_submitted_qc>June 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>August 12, 2018</last_update_submitted>
  <last_update_submitted_qc>August 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

